Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

由 Li, Yan, Connarn, Jamie N, Chen, Jian, Tong, Zeen, Palmisano, Maria, Zhou, Simon
發表在 Clin Pharmacol (2019)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects

由 Li, Yan, Liu, Liangang, Gomez, Diana, Chen, Jian, Tong, Zeen, Palmisano, Maria, Zhou, Simon
發表在 Pharmacol Res Perspect (2018)

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer

由 Rajeshkumar, N V, Yabuuchi, Shinichi, Pai, Shweta G, Tong, Zeen, Hou, Shihe, Bateman, Scott, Pierce, Daniel W, Heise, Carla, Von Hoff, Daniel D, Maitra, Anirban, Hidalgo, Manuel
發表在 Br J Cancer (2016)

Initial Testing (Stage 1) of the Tubulin Binding Agent Nanoparticle Albumin-Bound (nab) Paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP)

由 Houghton, Peter J., Kurmasheva, Raushan T., Kolb, E. Anders, Gorlick, Richard, Maris, John M., Wu, Jianrong, Tong, Zeen, Arnold, Michael A., Chatterjee, Moumita, Williams, Terence M., Smith, Malcolm A.
發表在 Pediatr Blood Cancer (2015)